• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Anthranilamides

Research Brief on 2-Amino-3-hydroxybenzamide (CAS: 16353-14-3): Recent Advances and Applications

2-Amino-3-hydroxybenzamide (CAS: 16353-14-3) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have highlighted its potential as a versatile scaffold for drug development, particularly in the context of enzyme inhibition and therapeutic agent design. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and applications in medicinal chemistry.

A study published in the Journal of Medicinal Chemistry (2023) explored the role of 2-Amino-3-hydroxybenzamide as a potent inhibitor of poly(ADP-ribose) polymerase (PARP), a key enzyme involved in DNA repair pathways. The research demonstrated that derivatives of this compound exhibit high selectivity and efficacy in targeting PARP-1 and PARP-2, making them promising candidates for cancer therapy, particularly in BRCA-mutated tumors. The study utilized molecular docking and in vitro assays to validate the binding affinity and inhibitory effects of 2-Amino-3-hydroxybenzamide derivatives.

Further investigations have revealed the compound's utility in neurodegenerative disease research. A 2024 study in ACS Chemical Neuroscience reported that 2-Amino-3-hydroxybenzamide derivatives could modulate amyloid-beta aggregation, a hallmark of Alzheimer's disease. The researchers employed nuclear magnetic resonance (NMR) spectroscopy and cell-based assays to elucidate the mechanism of action, suggesting that these derivatives could serve as lead compounds for developing neuroprotective agents.

In addition to its therapeutic potential, recent advancements in the synthetic chemistry of 2-Amino-3-hydroxybenzamide have been documented. A paper in Organic Letters (2023) described a novel, high-yield synthesis route using palladium-catalyzed C-H activation, which significantly improves the scalability and purity of the compound. This methodological breakthrough is expected to facilitate further pharmacological studies and industrial applications.

The safety profile and pharmacokinetic properties of 2-Amino-3-hydroxybenzamide have also been a focus of recent research. A preclinical study published in Toxicology and Applied Pharmacology (2024) evaluated the compound's toxicity and metabolic stability, revealing favorable results for oral bioavailability and minimal off-target effects. These findings underscore its potential as a viable drug candidate.

In conclusion, 2-Amino-3-hydroxybenzamide (CAS: 16353-14-3) continues to emerge as a molecule of high interest in chemical biology and pharmaceutical research. Its diverse applications—from cancer therapy to neurodegenerative disease intervention—coupled with recent synthetic and pharmacological advancements, position it as a promising candidate for future drug development. Ongoing research is expected to further elucidate its mechanisms and expand its therapeutic potential.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)